Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sun Pharmaceutical Industries Ltd. M&A Activity 2025

Mar 18, 2025

59215_rns_2025-03-18_ef761986-8420-477b-9b2e-3fff8099648f.pdf

M&A Activity

Open in viewer

Opens in your device viewer

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: [email protected] CIN: L24230GJ1993PLC019050

==> picture [66 x 73] intentionally omitted <==

March 18, 2025

National Stock Exchange of India Limited Scrip Symbol: SUNPHARMA

BSE Limited Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on Acquisition

Further to our intimation dated January 16, 2025, this is to inform that TARO Pharmaceuticals Inc., a subsidiary of Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as ‘Sun Pharma’), has completed 100% acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million.

For Sun Pharmaceutical Industries Limited

Anoop Digitally signed by Anoop Anjanikumar Anjanikumar Deshpande Date: 2025.03.18 12:21:08 Deshpande +05'30' (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.